Arena Pharmaceuticals Financial Statements (ARNA)
|
|
|
|
Report date
|
|
|
14.03.2018 |
28.02.2019 |
27.02.2020 |
23.02.2021 |
23.02.2022 |
|
23.02.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
21.3 |
18.0 |
806.4 |
0.319 |
0.054 |
|
0.054 |
|
Operating Income, bln rub |
|
|
-92.0 |
-144.8 |
482.7 |
-426.6 |
-612.3 |
|
-625.5 |
|
EBITDA, bln rub |
? |
|
-81.0 |
-130.2 |
515.9 |
-396.4 |
-608.4 |
|
-609.5 |
|
Net profit, bln rub |
? |
|
-91.4 |
-29.4 |
397.6 |
-404.7 |
-620.6 |
|
-617.4 |
|
|
OCF, bln rub |
? |
|
-66.6 |
-132.2 |
568.7 |
-353.1 |
-452.0 |
|
-452.0 |
|
CAPEX, bln rub |
? |
|
0.113 |
0.692 |
4.82 |
0.820 |
71.0 |
|
71.0 |
|
FCF, bln rub |
? |
|
-66.8 |
-132.9 |
563.9 |
-353.9 |
-523.0 |
|
-523.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
101.3 |
162.7 |
323.7 |
426.9 |
554.3 |
|
554.3 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
R&D, bln rub |
|
|
71.0 |
115.0 |
231.5 |
323.7 |
419.5 |
|
419.5 |
|
Interest expenses, bln rub |
|
|
6.12 |
5.70 |
4.79 |
4.52 |
4.16 |
|
3.09 |
|
|
Assets, bln rub |
|
|
339.3 |
686.9 |
1 174 |
1 191 |
784.7 |
|
784.7 |
|
Net Assets, bln rub |
? |
|
207.1 |
606.3 |
1 071 |
1 080 |
673.2 |
|
673.2 |
|
Debt, bln rub |
|
|
61.7 |
52.7 |
49.4 |
45.6 |
41.2 |
|
41.2 |
|
Cash, bln rub |
|
|
247.1 |
445.6 |
739.6 |
1 104 |
550.5 |
|
550.5 |
|
Net debt, bln rub |
|
|
-185.3 |
-392.9 |
-690.1 |
-1 058 |
-509.3 |
|
-509.3 |
|
|
Ordinary share price, rub |
|
|
34.0 |
39.0 |
45.4 |
76.8 |
92.9 |
|
94.0 |
|
Number of ordinary shares, mln |
|
|
33.0 |
47.0 |
51.7 |
54.8 |
54.8 |
|
61.4 |
|
|
Market cap, bln rub |
|
|
1 121 |
1 832 |
2 348 |
4 208 |
5 090 |
|
5 767 |
|
EV, bln rub |
? |
|
935 |
1 439 |
1 658 |
3 149 |
4 581 |
|
5 258 |
|
Book value, bln rub |
|
|
207 |
606 |
1 071 |
1 080 |
673 |
|
673 |
|
|
EPS, rub |
? |
|
-2.77 |
-0.62 |
7.69 |
-7.39 |
-11.3 |
|
-10.1 |
|
FCF/share, rub |
|
|
-2.02 |
-2.83 |
10.9 |
-6.46 |
-9.55 |
|
-8.52 |
|
BV/share, rub |
|
|
6.28 |
12.9 |
20.7 |
19.7 |
12.3 |
|
11.0 |
|
|
EBITDA margin, % |
? |
|
-379.7% |
-724.6% |
64.0% |
-124 249% |
-1 126 670% |
|
-1 128 657% |
|
Net margin, % |
? |
|
-428.4% |
-163.6% |
49.3% |
-126 876% |
-1 149 244% |
|
-1 143 404% |
|
FCF yield, % |
? |
|
-5.96% |
-7.25% |
24.0% |
-8.41% |
-10.3% |
|
-9.07% |
|
ROE, % |
? |
|
-44.1% |
-4.85% |
37.1% |
-37.5% |
-92.2% |
|
-91.7% |
|
ROA, % |
? |
|
-26.9% |
-4.28% |
33.9% |
-34.0% |
-79.1% |
|
-78.7% |
|
|
P/E |
? |
|
-12.3 |
-62.3 |
5.91 |
-10.4 |
-8.20 |
|
-9.34 |
|
P/FCF |
|
|
-16.8 |
-13.8 |
4.16 |
-11.9 |
-9.73 |
|
-11.0 |
|
P/S |
? |
|
52.5 |
102.0 |
2.91 |
13 190 |
94 260 |
|
106 798 |
|
P/BV |
? |
|
5.41 |
3.02 |
2.19 |
3.89 |
7.56 |
|
8.57 |
|
EV/EBITDA |
? |
|
-11.5 |
-11.1 |
3.21 |
-7.95 |
-7.53 |
|
-8.63 |
|
Debt/EBITDA |
|
|
2.29 |
3.02 |
-1.34 |
2.67 |
0.84 |
|
0.84 |
|
|
R&D/CAPEX, % |
|
|
62 821% |
16 623% |
4 804% |
39 480% |
591.0% |
|
591.0% |
|
|
CAPEX/Revenue, % |
|
|
0.53% |
3.85% |
0.60% |
257.1% |
131 459% |
|
131 459% |
|
| Arena Pharmaceuticals shareholders |
